UIH(SH:688271)2024-05-06 07:34Financial Performance - In 2023, the company achieved a revenue of CNY 11.411 billion, representing a year-on-year growth of 23.52%. The net profit attributable to shareholders was CNY 1.974 billion, with a growth of 19.21%. The gross margin for 2023 was 48.48%, an increase of 0.12 percentage points compared to the previous year [2][3]. - For Q1 2024, the company reported a revenue of CNY 2.350 billion, a year-on-year increase of 6.22%, and a net profit of CNY 0.363 billion, up by 10.20% [2][3]. Revenue Distribution - In 2023, domestic revenue reached CNY 9.733 billion, growing by 19.37%, while international revenue was CNY 1.03 billion, marking a 39.7% increase. The international market revenue accounted for 14.7% of total revenue, with a significant growth of 54.72% [2][3]. - Equipment revenue for 2023 was CNY 9.927 billion, up by 21.10%, while service revenue reached CNY 1.069 billion, growing by 42.78% [3][4]. Product Line Performance - The revenue breakdown by product line in 2023 included: CT revenue of CNY 4.066 billion, MR revenue of CNY 3.279 billion, MI revenue of CNY 1.552 billion, XR revenue of CNY 0.760 billion, and RT revenue of CNY 0.270 billion. MR revenue saw a notable increase of 58.5% [3][4]. - The company maintained its leading position in the Chinese market for medical imaging and radiation therapy equipment, with significant growth in high-end and ultra-high-end CT systems [3][4]. R&D and Innovation - In 2023, the company invested CNY 1.729 billion in R&D, with a workforce of 2,956 R&D personnel, accounting for 39.73% of total employees. The R&D investment is crucial for maintaining competitiveness and growth [4][5]. - The company launched over 120 innovative products by Q1 2024, with 49 products receiving CE certification and 44 products obtaining FDA approval [5][6]. Market Expansion - By the end of 2023, the company had established partnerships with over 40 institutions across more than 30 countries, contributing to over 1,300 global research publications [7][8]. - The company’s products served over 12,600 medical institutions in more than 65 countries and regions, with a focus on enhancing medical capabilities at various levels of healthcare institutions in China [8][9]. Future Outlook - The company aims to leverage technological innovations to enhance medical quality and efficiency, focusing on high intelligence, low cost, and early health solutions in the healthcare market [13][14]. - The company plans to strengthen its management system, enrich its product portfolio, and enhance brand influence to become a global leader in medical innovation [14][15].